Table 1 The content of the five recommendations
Number | Recommendations | Combined scores* |
|---|---|---|
6.2 | We suggest that medical institutions embed the evidencebased medicine database of children’s offlabel drugs into the hospital’s electronic medical record system to enhance evidencebased decisionmaking, practice, and management. (3; B) | 9117 |
6.1 | We suggest to develop an evidencebased medicine database for offlabel use drug use in children in China. (3; B) | 9116 |
4.1 | We suggest using the Benefit and Risk Assessment for Offlabel Use (BRAvO) decisionmaking framework. (2; B) | 9011 |
1.2 | Clinicians are recommended to refer to the published guidelines or consensus statements on the specific topic for children. (2; B) | 9008 |
4.2 | The risks associated with offlabel use of drugs vary between different age groups of children. It is recommended that clinicians pay particular attention on how to treat neonates and preterm infants. (1; A);Clinicians should consider the child’s age and the associated physiological, growth and development characteristics when prescribing drugs offlabel. (5; C) | 9008 |